



**Australian Government**

**Department of Health**

Therapeutic Goods Administration

# Reclassification of medical devices in direct contact with the heart, central circulatory and central nervous systems

Guidance on the transitional arrangements and obligations

Version 1.1, November 2021

**TGA** Health Safety  
Regulation

**Copyright**

© Commonwealth of Australia 2021

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to [tga.copyright@tga.gov.au](mailto:tga.copyright@tga.gov.au).

The purpose of this guidance is to help sponsors and manufacturers comply with the requirements of the therapeutic goods legislation.

This is a guide only, and sponsors and manufacturers are encouraged to familiarise themselves with the legislative and regulatory requirements in Australia. If necessary, seek professional advice as it is the responsibility of each sponsor and/or manufacturer to understand and comply with these requirements.

This document will evolve over time and updates and clarifications will be included as required. Feedback on the guidance is always welcome.

# Contents

<b>About this guidance</b>	<b>4</b>
Background	4
Requirements for reclassification	4
<b>Medical devices in direct contact with the heart, CCS or CNS</b>	<b>5</b>
Examples of devices to be reclassified to Class III	5
<b>What you need to do</b>	<b>6</b>
Medical devices included in the ARTG prior to 25 November 2021	6
Applications to include a medical device in the ARTG lodged before 25 November 2021	7
Cancelling your ARTG inclusion	7
Applications to include a new medical device on or after 25 November 2021	7
<b>Notifying the TGA</b>	<b>8</b>
<b>Class III applications for ARTG inclusion</b>	<b>8</b>
Kind of device: Class IIa vs Class III	8
What to include in your application	9
Fees	9
<b>If your inclusion application is not successful</b>	<b>10</b>
<b>When to cease supply using your old ARTG entry</b>	<b>10</b>

## About this guidance

This guidance aims to assist sponsors of **medical devices intended to be used in direct contact with the heart, central circulatory system (CCS) or the central nervous system (CNS)** with meeting their obligations and outlines transitional arrangements to help comply with new regulations.

From **25 November 2021** medical devices intended to be used in direct contact with the heart, central circulatory system (CCS) or the central nervous system (CNS) will be required to meet regulatory requirements demonstrating the safety and performance for **Class III medical devices**.

## Background

In early 2019 the Therapeutic Goods Administration (TGA) conducted a [public consultation seeking feedback](#) on a proposal to reclassify medical devices intended to be used in direct contact with the heart, central circulatory system (CCS) or the central nervous system (CNS). The proposed regulatory changes supported the commitment made in the [Australian Government Response to the Review of Medicines and Medical Devices Regulation](#) to align Australian medical device regulations, where possible and appropriate, with the European Union framework.

Stakeholders who responded to the public consultation were broadly supportive of the proposed changes and the [Therapeutic Goods Legislation Amendment \(2019 Measures No.1\) Regulations 2019](#) was made on 12 December 2019.

The [amendments](#) include the reclassification of all surgically invasive medical devices intended to be used in direct contact with the heart, CCS or CNS from Class IIa (low-medium risk) to Class III (high risk), effective from 25 November 2021.

Further regulatory [refinements](#) were made on 29 October 2021 to provide greater clarity around the regulation of these products.

## Requirements for reclassification

The requirements include:

- more detailed assessment of the manufacturer's quality management systems and assessment of technical documentation related to each device
- conformity assessment documents demonstrating procedures appropriate for a Class III device
- mandatory audit assessment by the TGA for device inclusion applications, including assessment of clinical evidence.

# Medical devices in direct contact with the heart, CCS or CNS

Medical devices in direct contact with the heart, CCS or CNS will be reclassified to Class III, regardless of the duration of action of the device (transient, short-term or long-term). This means that:

- medical devices used in direct contact with the **heart and CCS** which are intended for **transient or short-term use** will be reclassified from Class IIa (low-medium risk) to Class III (high risk)
- medical devices used in direct contact with the **CNS** which are intended for **transient use** will be reclassified from Class IIa to Class III.

Medical devices in direct contact with the heart, CCS or CNS that are intended for **long-term use** are **already classified as Class III** and there are no changes to the classification for these devices.

From 25 November 2021, the following amendments to the classification rules will apply:

## Subclause 3.2(3A) of Schedule 2:

*(3A) If the device is not a reusable surgical instrument and the device is intended by the manufacturer specifically to be used in direct contact with the heart, the central circulatory system or the central nervous system of a patient, the device is classified as Class III.*

## Paragraph 3.3(4)(b) of Schedule 2:

*If the device is intended by the manufacturer:*

*... (b) specifically to be used in direct contact with the heart, the central circulatory system or the central nervous system of a patient;*

*... the device is classified as Class III*



### Please note

There may be further updates to this guidance pending the outcome of the consultation on the definition of the Central Circulatory System (CCS).

## Examples of devices to be reclassified to Class III

- self-expanding valve prosthesis
- post-dilatation balloon catheter
- cardiac vent catheter
- central venous catheterisation kit
- cardiopulmonary cannulae.

Some examples of transient-use surgically invasive medical devices used in direct contact with the CNS include:

- flexible fiberoptic neuroscope
- rigid neuroscope
- automatic cranial perforator
- spinal needle.

## What you need to do

If you are a sponsor of a medical device that is used in direct contact with the heart, CCS or CNS, the action you will need to take to comply with the new regulations will depend on the status of your product:

- [Medical devices included in the ARTG prior to 25 November 2021](#)
- [Applications to include a medical device in the ARTG lodged before 25 November 2021](#)
- [Applications to include a new medical device in the ARTG on or after 25 November 2021](#)

## Medical devices included in the ARTG prior to 25 November 2021

If you have a medical device inclusion in the ARTG that will be reclassified, with a start date before 25 November 2021, transitional arrangements are in place to ensure that you can continue to supply your device while you apply for it to be included in the ARTG as a Class III medical device.

To continue to supply your device you must:

- [Notify the TGA before 25 May 2022](#) that you have an inclusion that will need to be reclassified
- [Submit an application](#) for your device to be included in the ARTG as a Class III medical device **before 1 November 2024**.



### Please note

If you do not intend to continue supplying the device, you should [cancel your ARTG inclusion](#) **before 25 May 2022**.

If you **notify** the TGA of your devices **before 25 May 2022** but you do not **submit an application** for a Class III inclusion **before 1 November 2024**, you must cease supplying your device from 1 November 2024 and cancel your inclusion.

## Applications to include a medical device in the ARTG lodged before 25 November 2021

If you have submitted an [application for inclusion](#) in the ARTG for a Class IIa device before 25 November 2021, your application will be assessed and the device will be included in the ARTG as a Class IIa device under the old classification rules.

To be eligible for the transitional arrangements to reclassify your device as a Class III device, you will need to:

- [Notify the TGA](#) that you have an inclusion that will need to be reclassified by whichever is the later date:
  - **Before 25 May 2022**
  - **Within 2 months of the start date of your ARTG entry**
- [Submit an application](#) for your device to be included in the ARTG as a Class III device **before 1 November 2024**.

### Cancelling your ARTG inclusion

If you **do not notify** the TGA before 25 May 2022 or within two months of the start date for your ARTG entry (whichever is the later date) of your intention to apply for the device to be included in the ARTG as a Class III device you will no longer be eligible for the transitional arrangements. You should:

- cease supply of your device from 25 May 2022 and
- [cancel your ARTG inclusion](#).

If you **notify** the TGA of your device before the due date, but you **do not submit an application** for a Class III inclusion **before 1 November 2024**, you must:

- cease supply of your device from 1 November 2024 and
- [cancel your ARTG inclusion](#).

## Applications to include a new medical device on or after 25 November 2021

Any [application for inclusion](#) of a new device, that is not yet included in the ARTG, submitted to the TGA **on or after 25 November 2021** must be submitted as an application for a Class III medical device.

For more information refer to the [Medical device ARTG inclusion process](#).

See below for information about the [differences between a Class IIa and a Class III medical device](#).

## Notifying the TGA

To notify the TGA that you have an ARTG inclusion for a device that needs to be reclassified, you will need to fill in the online form on our Consultation Hub:

<https://consultations.health.gov.au/tga/reclass-md-direct-contact-heart-ccs-cns>

The form will be available until 24 May 2022.

The information you will need to provide includes the existing ARTG number and for devices that will be newly classified as Class III medical devices, you will also need to provide UPIs for each device and/or variant.

## Class III applications for ARTG inclusion

In order to continue supplying your devices, you must submit your application for a Class III inclusion in the ARTG **before 1 November 2024**. If you have submitted your application before this date, but it has not yet been finalised by the TGA, you are able to continue to supply your devices using your Class IIa ARTG entry until a decision is made about your Class III application.



### Please note

You must submit a Class III application electronically through [TGA Business Services](#) using the Class III device application form. If you submit your application using any other form (for example, another classification form) your application will fail and your application fee will [not be refunded](#).

## Kind of device: Class IIa vs Class III

The application requirements for inclusion of a Class III device in the ARTG are different from the requirements for a Class IIa device.

Only devices of the same kind can be supplied under one ARTG entry.

Class IIa devices are considered to be of the same 'kind' and can be included in one ARTG entry when they have the same:


- sponsor
- manufacturer
- classification
- Global Medical Device Nomenclature (GMDN) System Code.

Class III devices must additionally have the same Unique Product Identifier (UPI) in order to be considered of the same "kind".



**Please note**

The devices included in your current Class IIa ARTG entry may have different UPIs. **You will require a separate Class III application for inclusion in the ARTG for each UPI.**



A Class III ARTG entry may still cover more than one device, but **only if** the:

- devices have the same UPI
- variation in the design of the devices is only to accommodate different patient anatomical requirements
- variation does not change the intended purpose of the device.

For more information about acceptable variants refer to [Kind of medical device](#).

## What to include in your application

To pass preliminary assessment, Class III applications for ARTG inclusion must be accompanied by conformity assessment documentation as outlined in [supporting documentation for inclusion of a medical device](#).

The specific documents that you are required to attach are outlined in the final column 'Documentation to be provided with the application (Evidence of product assessment)' of Table 2 in the [Use of market authorisation evidence from comparable overseas regulators / assessment bodies for medical devices \(including IVDs\)](#). This information must be provided in addition to the [manufacturer evidence](#).

Please ensure you allow sufficient time to obtain your conformity assessment documentation in order to submit your documents with your application.

If you do **not pass preliminary assessment**, your application **will be refused** and you will **not be able to transition** your device to the new classification.

## Fees

You will need to pay the relevant application fee and audit assessment fee.

You can request abridgement and [reduction of the assessment fee](#) of the audit assessment (including requests to abridge the level of audit if appropriate).



### Please note

If you do not have a TGA-issued conformity assessment certificate, your application will be selected for a [compulsory application audit](#). Compulsory application audits attract an **audit assessment fee**.

**Audit assessment fees** are listed in the TGA's [Schedule of fees and charges](#).

## If your inclusion application is not successful

If your inclusion application to transition your device to the new classification is not successful, you will be notified of the decision in writing and you will be provided the reasons for the decision.

If you are not satisfied with this decision, you may request reconsideration of this initial decision under section 60 of the [Therapeutic Goods Act 1989](#) within **90 days** of the decision.

If you are not satisfied with the reconsideration (reviewable decision), you may apply to the Administrative Appeals Tribunal or the court.

## When to cease supply using your old ARTG entry

If you do not meet your obligations under the transitional arrangements, you will need to cease supply of your device. The following table outlines the circumstances and timeframes:

### When to cease supply using an old ARTG entry

Circumstance	Timeframes
You have <b>not notified</b> the TGA that your device needs to be reclassified before 25 May 2022, or within two months of inclusion of your device under the old classification rules (whichever is the later date).	<b>Cease supply</b> of your devices <b>from 25 May 2022</b> or the date that is <b>2 months after the start date of your ARTG entry (whichever is the later date)</b> .
You have <b>not submitted an application for inclusion</b> in the ARTG to transition your device to the correct classification <b>before 1 November 2024</b> .	<b>Cease supply</b> of your devices <b>from 1 November 2024</b> .
Your application for inclusion of your device in the ARTG with the correct classification is unsuccessful.	<b>Cease supply</b> of your device from the time that you are <b>notified of the outcome</b> of your application.

## Version history

<b>Version</b>	<b>Description of change</b>	<b>Author</b>	<b>Effective date</b>
V1.0	Original publication	Medical Devices Authorisation Branch	August 2021
V1.1	Update due to regulatory refinements	Medical Devices Authorisation Branch	November 2021

## **Therapeutic Goods Administration**

PO Box 100 Woden ACT 2606 Australia  
Email: [info@tga.gov.au](mailto:info@tga.gov.au) Phone: 1800 020 653 Fax: 02 6203 1605  
<https://www.tga.gov.au>

Reference/Publication # [D19-6572481](#)